+

WO2003033506A1 - Aminoborane acid derivative and proteasome inhibitory drug containing the same - Google Patents

Aminoborane acid derivative and proteasome inhibitory drug containing the same Download PDF

Info

Publication number
WO2003033506A1
WO2003033506A1 PCT/JP2002/010450 JP0210450W WO03033506A1 WO 2003033506 A1 WO2003033506 A1 WO 2003033506A1 JP 0210450 W JP0210450 W JP 0210450W WO 03033506 A1 WO03033506 A1 WO 03033506A1
Authority
WO
WIPO (PCT)
Prior art keywords
aminoborane
acid derivative
same
proteasome inhibitory
remedy
Prior art date
Application number
PCT/JP2002/010450
Other languages
French (fr)
Japanese (ja)
Inventor
Hiroaki Satoh
Masahiro Ueno
Yoji Tachibana
Koichi Nakamaru
Ryotaro Kojima
Original Assignee
Kyorin Pharmaceutical Co., Ltd.
Nisshin Pharma Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyorin Pharmaceutical Co., Ltd., Nisshin Pharma Inc. filed Critical Kyorin Pharmaceutical Co., Ltd.
Priority to JP2003536245A priority Critical patent/JPWO2003033506A1/en
Publication of WO2003033506A1 publication Critical patent/WO2003033506A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

A novel aminoborane acid derivative represented by the general formula (1): (1) (wherein X is a group of the general formula (2), (3), or (4); (2) (3) (4) Y is the group of the formula (5) or (6); (5) (6) R1 and R2 are the same or different and each is C3-6 alkyl or C1-6 alkyl substituted by phenyl; Z1 is oxygen or sulfur; Z2 is hydrogen, methoxy, or halogeno; and m is 1 or 2), which has proteasome inhibitory activity. The compound having proteasome inhibitory activity is useful as an immunosuppressant, anti-inflammatory agent, antiallergic, remedy for autoimmune diseases, remedy for chronic inflammatory diseases such as inflammatory bowel diseases (ulcerative colitis and Crohn's disease), anticancer agent, or remedy for nerve degeneration diseases.
PCT/JP2002/010450 2001-10-12 2002-10-08 Aminoborane acid derivative and proteasome inhibitory drug containing the same WO2003033506A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2003536245A JPWO2003033506A1 (en) 2001-10-12 2002-10-08 Aminoboranoic acid derivatives and proteasome inhibitors containing the same

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2001-314731 2001-10-12
JP2001314731 2001-10-12

Publications (1)

Publication Number Publication Date
WO2003033506A1 true WO2003033506A1 (en) 2003-04-24

Family

ID=19132995

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2002/010450 WO2003033506A1 (en) 2001-10-12 2002-10-08 Aminoborane acid derivative and proteasome inhibitory drug containing the same

Country Status (2)

Country Link
JP (1) JPWO2003033506A1 (en)
WO (1) WO2003033506A1 (en)

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003059898A3 (en) * 2002-01-08 2004-02-26 Eisai Co Ltd Eponemycin and epoxomicin analogs and uses thereof
JP2007502304A (en) * 2003-08-14 2007-02-08 セファロン、インク． Proteasome inhibitors and methods of using them
EP2088205A1 (en) 2008-02-11 2009-08-12 Institut National De La Sante Et De La Recherche Medicale (Inserm) PSMB10: A diagnosis marker and therapeutic target of chronic rejection.
CN102127052A (en) * 2011-01-25 2011-07-20 浙江大学 Method for synthesizing 1,4-benzdioxan-2-carboxylic acid
KR101441703B1 (en) 2006-06-19 2014-09-17 오닉스 세라퓨틱스, 인크. Peptide Epoxy Ketone for Proteasome Inhibition
US9126997B1 (en) 2010-09-07 2015-09-08 Northwestern University Synergistic effect of glucocorticoid receptor agonists in combination with proteosome inhibitors for treating leukemia and myeloma
JP2016172768A (en) * 2016-06-27 2016-09-29 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Proteasome inhibitor
AU2016202747B2 (en) * 2004-03-30 2017-11-23 Millennium Pharmaceuticals, Inc. Synthesis of boronic ester and acid compounds
CN107474062A (en) * 2004-03-30 2017-12-15 千禧药品公司 The synthesis of the ester and acid compound of boron
WO2018159628A1 (en) * 2017-02-28 2018-09-07 国立大学法人北海道大学 Amino acid type acylborane and method for producing same
US10526351B2 (en) 2008-06-17 2020-01-07 Millennium Pharmaceuticals, Inc. Boronate ester compounds and pharmaceutical compositions thereof
JP2021526159A (en) * 2018-05-28 2021-09-30 チャンスー チア タイ フェンハイ ファーマシューティカル カンパニー リミテッドＪｉａｎｇｓｕ Ｃｈｉａ Ｔａｉ Ｆｅｎｇｈａｉ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ．， Ｌｔｄ． Synthesis and use of peptide boronic acid esters compounds
US11241448B2 (en) 2014-05-20 2022-02-08 Millennium Pharmaceuticals, Inc. Methods for cancer therapy

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6083903A (en) * 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6083903A (en) * 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7524883B2 (en) 2002-01-08 2009-04-28 Eisai R&D Management Co., Ltd. Eponemycin and epoxomicin analogs and uses thereof
WO2003059898A3 (en) * 2002-01-08 2004-02-26 Eisai Co Ltd Eponemycin and epoxomicin analogs and uses thereof
JP4917431B2 (en) * 2003-08-14 2012-04-18 セファロン、インク． Proteasome inhibitors and methods of using them
JP2007502304A (en) * 2003-08-14 2007-02-08 セファロン、インク． Proteasome inhibitors and methods of using them
CN107474062A (en) * 2004-03-30 2017-12-15 千禧药品公司 The synthesis of the ester and acid compound of boron
AU2016202747B2 (en) * 2004-03-30 2017-11-23 Millennium Pharmaceuticals, Inc. Synthesis of boronic ester and acid compounds
KR101441703B1 (en) 2006-06-19 2014-09-17 오닉스 세라퓨틱스, 인크. Peptide Epoxy Ketone for Proteasome Inhibition
EP2088205A1 (en) 2008-02-11 2009-08-12 Institut National De La Sante Et De La Recherche Medicale (Inserm) PSMB10: A diagnosis marker and therapeutic target of chronic rejection.
US10604538B2 (en) 2008-06-17 2020-03-31 Millenium Pharmaceuticals, Inc. Boronate ester compounds and pharmaceutical compositions thereof
US11485746B2 (en) 2008-06-17 2022-11-01 Millennium Pharmaceuticals, Inc. Boronate ester compounds and pharmaceutical compositions thereof
US10526351B2 (en) 2008-06-17 2020-01-07 Millennium Pharmaceuticals, Inc. Boronate ester compounds and pharmaceutical compositions thereof
US9126997B1 (en) 2010-09-07 2015-09-08 Northwestern University Synergistic effect of glucocorticoid receptor agonists in combination with proteosome inhibitors for treating leukemia and myeloma
CN102127052A (en) * 2011-01-25 2011-07-20 浙江大学 Method for synthesizing 1,4-benzdioxan-2-carboxylic acid
US11241448B2 (en) 2014-05-20 2022-02-08 Millennium Pharmaceuticals, Inc. Methods for cancer therapy
JP2016172768A (en) * 2016-06-27 2016-09-29 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Proteasome inhibitor
JPWO2018159628A1 (en) * 2017-02-28 2019-12-26 国立大学法人北海道大学 Amino acid type acylborane and method for producing the same
WO2018159628A1 (en) * 2017-02-28 2018-09-07 国立大学法人北海道大学 Amino acid type acylborane and method for producing same
JP7244921B2 (en) 2017-02-28 2023-03-23 国立大学法人北海道大学 Amino acid-type acylborane and method for producing the same
JP2021526159A (en) * 2018-05-28 2021-09-30 チャンスー チア タイ フェンハイ ファーマシューティカル カンパニー リミテッドＪｉａｎｇｓｕ Ｃｈｉａ Ｔａｉ Ｆｅｎｇｈａｉ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ．， Ｌｔｄ． Synthesis and use of peptide boronic acid esters compounds
JP7314259B2 (en) 2018-05-28 2023-07-25 チャンスー チア タイ フェンハイ ファーマシューティカル カンパニー リミテッド Synthesis and use of peptide boronic ester compounds

Also Published As

Publication number Publication date
JPWO2003033506A1 (en) 2005-02-03

Similar Documents

Publication Publication Date Title
WO2005092895A3 (en) Alpha aryl or heteroaryl methyl beta piperidino propanoic acid compounds as orl1-receptor antagonists
MY137944A (en) Specific glucocorticoid compounds having anti-inflammatory activity
EP1396493A4 (en) Heterocyclic compounds
WO2005037825A3 (en) Protein kinase inhibitors
WO2003033506A1 (en) Aminoborane acid derivative and proteasome inhibitory drug containing the same
WO2005018557A3 (en) Substituted pyridinones
WO2005060972A3 (en) Pyrrolo [2,3-d] pyrimidine compounds for treating transplant rejection
EP1953154A4 (en) Morpholine type cinnamide compound
WO2006024486A3 (en) Amide derivatives of 3-phenyl dihydropyrimido[4,5-d]pyrimidinones, their manufacture and use as pharmaceutical agents
NZ541974A (en) Nucleotide phosphoramidates as anticancer agents
TW200615266A (en) Organic compounds
WO2006005609A3 (en) Substituted oxindol derivatives and medicaments containing the same
EP1679309A4 (en) Antistress drug and medical use thereof
TW200745034A (en) New compounds
WO2004058679A3 (en) Ligands of adenine nucleotide translocase (ant) and compositions and methods related thereto
NO20055092L (en) Substituted pyrimid ions
EP1839662A4 (en) ANTITUMOR AGENT
WO2005040171A8 (en) Pyrazolo and imidazo-pyrimidine derivatives
CA2336412A1 (en) Medicament for treatment of diabetes
WO2005115470A3 (en) PHARMACEUTICAL COMPOSITIONS COMPRISING β-CARBOLINE DERIVATIVES AND USE THEREOF FOR THE TREATMENT OF CANCER
TW200616961A (en) Carbostyril compound
EP1634874A4 (en) Imidazolidine derivative
TW200637552A (en) Macrocyclic analogs for the treatment of immunoregulatory disorders and respiratory diseases
WO2004050035A3 (en) Benzimidazoles and analogs thereof as antivirals
NO20063111L (en) Process for the preparation of thiazole pyrimidines

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VC VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2003536245

Country of ref document: JP

122 Ep: pct application non-entry in european phase
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载